Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What the H.B. Fuller Deal Means for Advanced Medical Solutions (LSE:AMS) and the FTSE AIM All Share Index

Advanced Medical Solutions develops and manufactures products for the surgical, wound care and wound closure markets. Its portfolio includes tissue adhesives, sutures, haemostats and advanced wound dressings, sold to hospitals and healthcare providers around the world, both under its own brands and through partners. …

Ankur Sharma | 08 October 2026

What Anpario's (LSE:ANP) Latest Interim Results Signal for Its Place on the FTSE AIM All Share Index

Anpario develops, manufactures and sells feed additives designed to support animal health, nutrition and productivity, with a focus on natural products. Its range includes products that support gut health and help manage the effects of mycotoxins, which are toxins produced by moulds in animal …

Ankur Sharma | 08 October 2026

Why AOTI (LSE:AOTI) Is in Focus on the FTSE AIM All Share Index After US Coverage Wins

AOTI develops and sells TWO2, a topical wound oxygen therapy system designed to treat chronic wounds such as diabetic foot ulcers. The therapy delivers oxygen directly to the wound surface and is intended for home use. The company, which operates primarily in the United …

Ankur Sharma | 08 October 2026

What Aptamer Group (LSE:APTA) Investors Expect From Next Week's Results on the FTSE AIM All Share Index

Aptamer develops Optimer binders, engineered nucleic acid molecules designed as an alternative to antibodies. The company provides fee-for-service discovery and development work for pharmaceutical, diagnostics and biotechnology customers, and is increasingly seeking to license its technology so that it earns recurring, higher-margin income. Its …

Ankur Sharma | 08 October 2026

What Is Driving Interest in 4basebio (LSE:4BB) on the FTSE AIM All Share Index

Together, these updates suggest a company moving from platform development towards commercial relationships with established players in advanced therapies.

Ankur Sharma | 08 October 2026

How Abingdon Health (LSE:ABDX) Is Building Scale on the FTSE AIM All Share Index

Abingdon Health develops and manufactures rapid diagnostic tests, particularly lateral flow tests, which give quick results from samples such as blood, saliva or urine. Much of itsBusinessinvolves providing contract development and manufacturing services to other organisations that want to bring their own tests to …

Ankur Sharma | 08 October 2026

Diaceutics (LSE:DXRX) in Focus as Major Shareholder Raises Voting Stake

Diaceutics has disclosed a change in major ownership after Gresham House Asset Management increased its voting-rights position to 18.23%, from 17.02% previously. The change follows a period in which the precision-medicine commercialisation company has been highlighting strongerRecurring Revenuevisibility and expansion of its data-led platform.

Ankur Sharma | 08 October 2026

Futura Medical (LSE:FUM) in Focus as Positive Eroxon Intense Testing Supports 2027 Launch Plan

Futura Medical reported positive results from an additional home-user test of its Eroxon Intense formulation and optimised presentation. The company says the revised presentation improved key user-reported performance measures compared with the earlier Intense presentation and the current Eroxon formulation, supporting plans for commercialisation …

Ankur Sharma | 08 October 2026

What Optima Health (LSE:OPT) Reveals Following Occupational Health Scale Acquisitions and Service Expansions

Optima Health plc (LSE:OPT) has achieved transformative operational scale, establishing itself as the undisputedMarket Leaderin United Kingdom occupational health and employee clinical wellbeing services following its landmark admission to the London Stock Exchange's AIM market. The healthcare services group provides corporate occupational health assessments, …

Ankur Sharma | 07 October 2026

What Physiomics (LSE:PYC) Announces in Strategic Oncology Modelling Partnerships With Research Institutes

Physiomics plc (LSE:PYC) continues to demonstrate operational progress in computational oncology, entering strategic collaborations and deploying its proprietary mathematical modeling software to optimize preclinical and clinicalDrug Developmentfor global biopharmaceutical clients. Quoted on the AIM market of the London Stock Exchange, the computational biology specialist …

Ankur Sharma | 07 October 2026
Support

Hi! How can we help you today?

Loading…